The productivity of our internal discovery capability has enabled us to generate a pipeline of both topical and systemic boron-based compounds. We have discovered seven product candidates currently in development. Our lead product candidates include two topically administered dermatologic compounds—tavaborole (formerly AN2690), an antifungal for the treatment of onychomycosis, and AN2728 a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, we are developing AN2718 and AN2898 as backup compounds to tavaborole and AN2728, respectively. We have also discovered three compounds that are in development with our partners: GSK2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram- negative bacteria, is being developed by GlaxoSmithKline; AN8194 an animal health product candidate is being developed by Eli Lilly and Company; and AN5568 (also referred to as SCYX-7158) is being developed by the Drugs for Neglected Diseases initiative (DNDi) for the treatment of sleeping sickness. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.